comparemela.com
Home
Live Updates
Ipsen Delivers Strong H1 2022 Results and Upgrades Its Full-
Ipsen Delivers Strong H1 2022 Results and Upgrades Its Full-
Ipsen Delivers Strong H1 2022 Results and Upgrades Its Full-Year Guidance
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, presents its financial results for the first half of 2022: H1 2022 financial results
Related Keywords
Ukraine ,
Norway ,
Saclay ,
France General ,
France ,
Japan ,
Shanghai ,
China ,
United States ,
Paris ,
Algeria ,
Liechtenstein ,
Russia ,
Germany ,
Iceland ,
Italy ,
Cambridge ,
Cambridgeshire ,
United Kingdom ,
Ireland ,
Spain ,
Switzerland ,
America ,
American ,
Ipsen Cabometyx ,
Mayoly Spindler ,
Gwenan White ,
Ioana Piscociu ,
David Loew ,
Ipsen Euronext ,
Other Business Development ,
Public Affairs ,
Company Social Responsibility ,
Global Leadership Team ,
Service Saa ,
Regulatory News ,
Consumer Healthcare ,
New Drug Application ,
Chief Executive Officer ,
Regulated Information ,
Investor Relations ,
Priority Review ,
Prescription Drug User Fee Act ,
Social Responsibility ,
Generation Ipsen ,
Red Cross ,
Rare Disease ,
With Specialty Care ,
Sponsored Leveli American Depositary Receipt ,
North America ,
Blueprint Medicines ,
Financial Assets ,
Revolving Credit Facility ,
Corporate Social Responsibility ,
Commercial Paper ,
Business Development ,
French Autorit ,
Des March ,
Registration Document ,
Relations Manager ,
Vice President ,
Global Media Relations ,
Lipsen ,
Elivers ,
Strong ,
022 ,
Results ,
Upgrades ,
Bull ,
Ear ,
Guidance ,